Cargando…

Soluble and cell-based markers of immune checkpoint inhibitor-associated nephritis

BACKGROUND: Non-invasive biomarkers of immune checkpoint inhibitor-associated acute tubulointerstitial nephritis (ICI-nephritis) are urgently needed. Because ICIs block immune checkpoint pathways that include cytotoxic T lymphocyte antigen 4 (CTLA4), we hypothesized that biomarkers of immune dysregu...

Descripción completa

Detalles Bibliográficos
Autores principales: Sise, Meghan E, Wang, Qiyu, Seethapathy, Harish, Moreno, Daiana, Harden, Destiny, Smith, R Neal, Rosales, Ivy A, Colvin, Robert B, Chute, Sarah, Cornell, Lynn D, Herrmann, Sandra M, Fadden, Riley, Sullivan, Ryan J, Yang, Nancy J, Barmettler, Sara, Wells, Sophia, Gupta, Shruti, Villani, Alexandra-Chloe, Reynolds, Kerry L, Farmer, Jocelyn
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9853261/
https://www.ncbi.nlm.nih.gov/pubmed/36657813
http://dx.doi.org/10.1136/jitc-2022-006222
_version_ 1784872854342336512
author Sise, Meghan E
Wang, Qiyu
Seethapathy, Harish
Moreno, Daiana
Harden, Destiny
Smith, R Neal
Rosales, Ivy A
Colvin, Robert B
Chute, Sarah
Cornell, Lynn D
Herrmann, Sandra M
Fadden, Riley
Sullivan, Ryan J
Yang, Nancy J
Barmettler, Sara
Wells, Sophia
Gupta, Shruti
Villani, Alexandra-Chloe
Reynolds, Kerry L
Farmer, Jocelyn
author_facet Sise, Meghan E
Wang, Qiyu
Seethapathy, Harish
Moreno, Daiana
Harden, Destiny
Smith, R Neal
Rosales, Ivy A
Colvin, Robert B
Chute, Sarah
Cornell, Lynn D
Herrmann, Sandra M
Fadden, Riley
Sullivan, Ryan J
Yang, Nancy J
Barmettler, Sara
Wells, Sophia
Gupta, Shruti
Villani, Alexandra-Chloe
Reynolds, Kerry L
Farmer, Jocelyn
author_sort Sise, Meghan E
collection PubMed
description BACKGROUND: Non-invasive biomarkers of immune checkpoint inhibitor-associated acute tubulointerstitial nephritis (ICI-nephritis) are urgently needed. Because ICIs block immune checkpoint pathways that include cytotoxic T lymphocyte antigen 4 (CTLA4), we hypothesized that biomarkers of immune dysregulationpreviously defined in patients with congenital CTLA4 deficiency, including elevated soluble interleukin-2 receptor alpha (sIL-2R) and flow cytometric cell-based markers of B and T cell dysregulation in peripheral blood may aid the diagnosis of ICI-nephritis. METHODS: A retrospective cohort of patients diagnosed with ICI-nephritis was compared with three prospectively enrolled control cohorts: ICI-treated controls without immune-related adverse events, patients not on ICIs with hemodynamic acute kidney injury (hemodynamic AKI), and patients not on ICIs with biopsy proven acute interstitial nephritis from other causes (non-ICI-nephritis). sIL-2R level and flow cytometric parameters were compared between groups using Wilcoxon rank sum test or Kruskal-Wallis test. Receiver operating characteristic curves were generated to define the accuracy of sIL-2R and flow cytometric biomarkers in diagnosing ICI-nephritis. The downstream impact of T cell activation in the affected kidney was investigated using archived biopsy samples to evaluate the gene expression of IL2RA, IL-2 signaling, and T cell receptor signaling in patients with ICI-nephritis compared with other causes of drug-induced nephritis, acute tubular injury, and histologically normal controls. RESULTS: sIL-2R level in peripheral blood was significantly higher in patients with ICI-nephritis (N=24) (median 2.5-fold upper limit of normal (ULN), IQR 1.9–3.3), compared with ICI-treated controls (N=10) (median 0.8-fold ULN, IQR 0.5–0.9, p<0.001) and hemodynamic AKI controls (N=6) (median 0.9-fold-ULN, IQR 0.7–1.1, p=0.008). A sIL-2R cut-off point of 1.75-fold ULN was highly diagnostic of ICI-nephritis (area under the curve >96%) when compared with either ICI-treated or hemodynamic AKI controls. By peripheral blood flow cytometry analysis, lower absolute CD8+T cells, CD45RA+CD8+ T cells, memory CD27+B cells, and expansion of plasmablasts were prominent features of ICI-nephritis compared with ICI-treated controls. Gene expressions for IL2RA, IL-2 signaling, and T cell receptor signaling in the kidney tissue with ICI-nephritis were significantly higher compared with controls. CONCLUSION: Elevated sIL-2R level and flow cytometric markers of both B and T cell dysregulation may aid the diagnosis of ICI-nephritis.
format Online
Article
Text
id pubmed-9853261
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher BMJ Publishing Group
record_format MEDLINE/PubMed
spelling pubmed-98532612023-01-21 Soluble and cell-based markers of immune checkpoint inhibitor-associated nephritis Sise, Meghan E Wang, Qiyu Seethapathy, Harish Moreno, Daiana Harden, Destiny Smith, R Neal Rosales, Ivy A Colvin, Robert B Chute, Sarah Cornell, Lynn D Herrmann, Sandra M Fadden, Riley Sullivan, Ryan J Yang, Nancy J Barmettler, Sara Wells, Sophia Gupta, Shruti Villani, Alexandra-Chloe Reynolds, Kerry L Farmer, Jocelyn J Immunother Cancer Immunotherapy Biomarkers BACKGROUND: Non-invasive biomarkers of immune checkpoint inhibitor-associated acute tubulointerstitial nephritis (ICI-nephritis) are urgently needed. Because ICIs block immune checkpoint pathways that include cytotoxic T lymphocyte antigen 4 (CTLA4), we hypothesized that biomarkers of immune dysregulationpreviously defined in patients with congenital CTLA4 deficiency, including elevated soluble interleukin-2 receptor alpha (sIL-2R) and flow cytometric cell-based markers of B and T cell dysregulation in peripheral blood may aid the diagnosis of ICI-nephritis. METHODS: A retrospective cohort of patients diagnosed with ICI-nephritis was compared with three prospectively enrolled control cohorts: ICI-treated controls without immune-related adverse events, patients not on ICIs with hemodynamic acute kidney injury (hemodynamic AKI), and patients not on ICIs with biopsy proven acute interstitial nephritis from other causes (non-ICI-nephritis). sIL-2R level and flow cytometric parameters were compared between groups using Wilcoxon rank sum test or Kruskal-Wallis test. Receiver operating characteristic curves were generated to define the accuracy of sIL-2R and flow cytometric biomarkers in diagnosing ICI-nephritis. The downstream impact of T cell activation in the affected kidney was investigated using archived biopsy samples to evaluate the gene expression of IL2RA, IL-2 signaling, and T cell receptor signaling in patients with ICI-nephritis compared with other causes of drug-induced nephritis, acute tubular injury, and histologically normal controls. RESULTS: sIL-2R level in peripheral blood was significantly higher in patients with ICI-nephritis (N=24) (median 2.5-fold upper limit of normal (ULN), IQR 1.9–3.3), compared with ICI-treated controls (N=10) (median 0.8-fold ULN, IQR 0.5–0.9, p<0.001) and hemodynamic AKI controls (N=6) (median 0.9-fold-ULN, IQR 0.7–1.1, p=0.008). A sIL-2R cut-off point of 1.75-fold ULN was highly diagnostic of ICI-nephritis (area under the curve >96%) when compared with either ICI-treated or hemodynamic AKI controls. By peripheral blood flow cytometry analysis, lower absolute CD8+T cells, CD45RA+CD8+ T cells, memory CD27+B cells, and expansion of plasmablasts were prominent features of ICI-nephritis compared with ICI-treated controls. Gene expressions for IL2RA, IL-2 signaling, and T cell receptor signaling in the kidney tissue with ICI-nephritis were significantly higher compared with controls. CONCLUSION: Elevated sIL-2R level and flow cytometric markers of both B and T cell dysregulation may aid the diagnosis of ICI-nephritis. BMJ Publishing Group 2023-01-19 /pmc/articles/PMC9853261/ /pubmed/36657813 http://dx.doi.org/10.1136/jitc-2022-006222 Text en © Author(s) (or their employer(s)) 2023. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ. https://creativecommons.org/licenses/by-nc/4.0/This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See http://creativecommons.org/licenses/by-nc/4.0/ (https://creativecommons.org/licenses/by-nc/4.0/) .
spellingShingle Immunotherapy Biomarkers
Sise, Meghan E
Wang, Qiyu
Seethapathy, Harish
Moreno, Daiana
Harden, Destiny
Smith, R Neal
Rosales, Ivy A
Colvin, Robert B
Chute, Sarah
Cornell, Lynn D
Herrmann, Sandra M
Fadden, Riley
Sullivan, Ryan J
Yang, Nancy J
Barmettler, Sara
Wells, Sophia
Gupta, Shruti
Villani, Alexandra-Chloe
Reynolds, Kerry L
Farmer, Jocelyn
Soluble and cell-based markers of immune checkpoint inhibitor-associated nephritis
title Soluble and cell-based markers of immune checkpoint inhibitor-associated nephritis
title_full Soluble and cell-based markers of immune checkpoint inhibitor-associated nephritis
title_fullStr Soluble and cell-based markers of immune checkpoint inhibitor-associated nephritis
title_full_unstemmed Soluble and cell-based markers of immune checkpoint inhibitor-associated nephritis
title_short Soluble and cell-based markers of immune checkpoint inhibitor-associated nephritis
title_sort soluble and cell-based markers of immune checkpoint inhibitor-associated nephritis
topic Immunotherapy Biomarkers
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9853261/
https://www.ncbi.nlm.nih.gov/pubmed/36657813
http://dx.doi.org/10.1136/jitc-2022-006222
work_keys_str_mv AT sisemeghane solubleandcellbasedmarkersofimmunecheckpointinhibitorassociatednephritis
AT wangqiyu solubleandcellbasedmarkersofimmunecheckpointinhibitorassociatednephritis
AT seethapathyharish solubleandcellbasedmarkersofimmunecheckpointinhibitorassociatednephritis
AT morenodaiana solubleandcellbasedmarkersofimmunecheckpointinhibitorassociatednephritis
AT hardendestiny solubleandcellbasedmarkersofimmunecheckpointinhibitorassociatednephritis
AT smithrneal solubleandcellbasedmarkersofimmunecheckpointinhibitorassociatednephritis
AT rosalesivya solubleandcellbasedmarkersofimmunecheckpointinhibitorassociatednephritis
AT colvinrobertb solubleandcellbasedmarkersofimmunecheckpointinhibitorassociatednephritis
AT chutesarah solubleandcellbasedmarkersofimmunecheckpointinhibitorassociatednephritis
AT cornelllynnd solubleandcellbasedmarkersofimmunecheckpointinhibitorassociatednephritis
AT herrmannsandram solubleandcellbasedmarkersofimmunecheckpointinhibitorassociatednephritis
AT faddenriley solubleandcellbasedmarkersofimmunecheckpointinhibitorassociatednephritis
AT sullivanryanj solubleandcellbasedmarkersofimmunecheckpointinhibitorassociatednephritis
AT yangnancyj solubleandcellbasedmarkersofimmunecheckpointinhibitorassociatednephritis
AT barmettlersara solubleandcellbasedmarkersofimmunecheckpointinhibitorassociatednephritis
AT wellssophia solubleandcellbasedmarkersofimmunecheckpointinhibitorassociatednephritis
AT guptashruti solubleandcellbasedmarkersofimmunecheckpointinhibitorassociatednephritis
AT villanialexandrachloe solubleandcellbasedmarkersofimmunecheckpointinhibitorassociatednephritis
AT reynoldskerryl solubleandcellbasedmarkersofimmunecheckpointinhibitorassociatednephritis
AT farmerjocelyn solubleandcellbasedmarkersofimmunecheckpointinhibitorassociatednephritis